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Description of the technology
Elispot is a workhorse for functional analysis of single
immune cells. Originally established for the enumeration
of specific antibody-secreting B cells in 1983 [1], the
technology has been expanded to the analysis of T cells,
NK cells and monocytes. The assay is typically carried
out in 96 well plates with a nitrocellulose or PVDF
membrane, which is coated with an antibody that is
directed against the analyte of interest. Cells and stimu-
lants are added to the plate, and secreted analyte is
captured in the immediate surroundings of the cell.
After cell removal, bound analyte is made visible via the
addition of a biotinylated secondary antibody, avidin-
enzyme complex and substrate that precipitates onto the
membrane and forms spots which can be automatically
enumerated. Each spot represents one cell that secreted
the analyte. The most common analytes investigated
today are cytokines (IFNɣ, IL-2, IL-5, IL-10, IL-17,
Granzyme B, TNF, GM-CSF and many more) and
immunoglobulins. Others can also be evaluated, such
as chemokines (e.g., CXCL8) or apolipoproteins.
The hallmark of the assay is its sensitivity allowing the
detection of antigen-specific immune cells in very low
frequencies. In contrast to other assays, Elispot measures
cells that actually secrete analytes without impairment
by receptor binding or protease activity. The assay is
easy to perform and transferable, and can be adapted to
high throughput. While it was historically limited to the
assessment of one parameter per assay, it has now been
expanded to the simultaneous assessment of 2 or even 3
parameters in one well by the introduction of fluores-
cent dyes in the detection cascade (Fluorospot), allowing
the identification of up to 7 subsets of immune cells inCorrespondence: sylvia@zellnet.com
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provided the original work is properly creditedone well with similar ease of performance as for the
enzymatic Elispot evaluating just one parameter (Fig. 1).
Because of its substantial penetration of translational
research, Elispot underwent rigorous harmonization
efforts led by the cancer immunotherapy field [2], and it
is the only functional immune monitoring assay for
which a proficiency panel program has been made avail-
able for any laboratory independent of affiliation or
scientific background (www.proficiencypanel.com).
Lastly, the Elispot assay performance can readily be
standardized, qualified, and, if required, validated accord-
ing to the International Congress of Harmonization (ICH)
guidelines [3].Type of data obtained/readout
After automated evaluation, spot counts are obtained
which represent the number of cells that secreted the
analyte of interest per cells plated into a well. Each test-
ing conditioning (or antigenic stimulus) is tested separ-
ately, and compared to the negative control counts (cells
without antigenic stimulus or with negative control
stimulus). The response rate can be determined via em-
pirical rules or statistical testing. Empirical rules present
an ad hoc tool with set thresholds based on observations
from a study (e.g., more than 10 spots/well and at least
3x above background reactivity). An excellent example
on how to establish empirical rules for Elispot has been
given elsewhere [4]. For appropriate statistical testing,
the variability of Elispot data and the fact that their nor-
mal distribution cannot be assumed due to the low
number of replicates need to be taken into consider-
ation. Hence non-parametric testing as with the
Distribution-free Resampling (DFR) method is recom-
mended [5], for which a free online tool has been made
available (http://www.scharp.org/zoe/runDFR/). Further,
automated analysis of Elispot plates also provides infor-
mation on the spot size and spot staining intensity,distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
.
Fig. 1 Overlay image of a triple color Fluorospot well. PBMC were
tested for the secretion of IFNɣ (FITC spots, green), IL-17A (Cy3,
orange), and IL-22 (Cy5, red). The appropriate multi-level evaluation of
such sample reveals 7 sub-populations (3 single secretors, 3 dual
secretors, 1 triple secretor [11])
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lyte secreted during the assay time.
Limitations of the approach
Elispot does not or only to a very limited degree allow
the phenotypic analysis of cells that are being assessed.
Sub-populations of cells can be isolated prior to the
assay in order to identify the responding cell population,
what may complicate the antigen presentation require-
ments for the assay. Blocking with MHC class I or class
II antibodies provides another, restricted alternative.
As of today, the functional analysis of immune cells is
restricted to a maximum of three parameters, pending
the availability of appropriate Fluorospot kits.
Types of samples needed and special issues
pertaining to samples
Single cell suspensions are needed for the assay, such as
PBMC or TILs. Cells can be tested directly ex vivo with-
out any pretreatment or expansion (even though in vitro
expansion may be used for the detection of extremely
rare cells). Alternatively, frozen cells can be used after
proper thawing and recovery [6]. Similar to the func-
tional assessment of cells by flow cytometry, sample
integrity is crucial to the success of Elispot. Whole blood
is not suitable for the assay, and needs to be processed
for PBMC isolation within a short time frame (typically
less than 8 h) in order to prevent the effects of granulo-
cyte activation on T cell functionality.Level of evidence
About 5,000 publications exist on the Elispot technique
or its use in research, translational or clinical settings.
There is a growing body of literature available demon-
strating the correlation of the clinical outcome of
patients in immunotherapeutic trials with Elispot data
[7–9]. Its general clinical validity has further been under-
lined with the approval of a diagnostic Elispot kit in
tuberculosis [10]. The assay is conducted under research
as well as GLP/GMP conditions.
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